Introduction: Daratumumab (DARA), a human, IgGκ monoclonal antibody targeting CD38, is
approved either as a single agent or in combination with anti-myeloma regimens for newly …

Minimal residual disease (MRD) has become an increasingly prevalent and important entity
in multiple myeloma (MM). Despite deepening responses to frontline therapy, roughly 75 …

Importance A thorough understanding of the optimal role and sequence of agents for
treatment of multiple myeloma (MM) requires knowledge of the use and rate of postprotocol …

Multiple myeloma (MM) is associated with both cellular and humoral immune deficiencies
and, despite significant advances in treatment, remains an incurable disease. Regulatory T …

Cell-to-cell communication is a fundamental process in every multicellular organism. In
addition to membrane-bound and released factors, the sharing of cytosolic components …

Outcomes in multiple myeloma (MM) have improved dramatically in the last two decades
with the advent of novel therapies including immunomodulatory agents (IMiDs), proteasome …

CD38 and B-cell maturation antigens (BCMAs) are prevalently expressed on neoplastic
plasma cells in multiple myeloma (MM), making them ideal therapeutic targets. Anti-CD38 …

The increase in the number of therapeutic alternatives for both newly diagnosed and
relapsed/refractory multiple myeloma (RRMM) patients has widened the clinical scenario …

Multiple myeloma (MM) remains an incurable hematological malignancy characterized by
clonal proliferation of malignant plasma cells in bone marrow. In the last 20 years, the …

The treatment options in multiple myeloma (MM) has changed dramatically over the past
decade with the development of novel agents such as proteasome inhibitors (PIs); …